Coexpression of vascular endothelial growth factor and interleukin-1 receptor antagonist for improved human islet survival and function

Xiangxu Jia, Kun Cheng, Ram I. Mahato

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Ex vivo gene therapy approaches can improve the outcome of islet transplantation for treating type I diabetes. We have recently shown improvement in islet survival and function following ex vivo infection of islets with a mixture of adenoviral vectors encoding human vascular endothelial growth factor (Adv-hVEGF) and human interleukin-1 receptor antagonist (Adv-hIL-1Ra). In this study, we constructed a bicistronic vector encoding these two genes (phVEGF-hIL-1Ra) by cloning hIL-1Ra under the cytomegalovirus (CMV) promoter and hVEGF under the elongation factor-1α (EF-1 α) promoter in pBudCE4.1 vector. There was dose and time dependent expression of hVEGF and hIL-1Ra at both mRNA and protein levels after transfection with human islets. Transfected islets were viable, as evidenced by insulin release upon glucose challenge. Coexpression of hVEGF and hIL-1Ra suppressed nitric oxide production, total caspases, apoptosis, and necrosis in the presence of inflammatory cytokine cocktail consisting of IL-1β, TNFα, and IFNγ. In conclusion, our results indicated that coexpression of growth factor and antiapoptic genes can improve islet survival and function.

Original languageEnglish (US)
Pages (from-to)199-207
Number of pages9
JournalMolecular Pharmaceutics
Volume4
Issue number2
DOIs
StatePublished - Mar 1 2007

Fingerprint

Interleukin-1 Receptors
Vascular Endothelial Growth Factor A
Peptide Elongation Factor 1
Islets of Langerhans Transplantation
Survival
Caspases
Cytomegalovirus
Type 1 Diabetes Mellitus
Interleukin-1
Genetic Therapy
Genes
Transfection
Organism Cloning
Intercellular Signaling Peptides and Proteins
Nitric Oxide
Necrosis
Insulin
Apoptosis
Cytokines
Glucose

Keywords

  • Bicistronic plasmid
  • Human islet
  • Insulin release
  • Real-time RT-PCR
  • hIL-1Ra
  • hVEGF

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Coexpression of vascular endothelial growth factor and interleukin-1 receptor antagonist for improved human islet survival and function. / Jia, Xiangxu; Cheng, Kun; Mahato, Ram I.

In: Molecular Pharmaceutics, Vol. 4, No. 2, 01.03.2007, p. 199-207.

Research output: Contribution to journalArticle

@article{a729dec4366b48c9a1cf30ab31800f37,
title = "Coexpression of vascular endothelial growth factor and interleukin-1 receptor antagonist for improved human islet survival and function",
abstract = "Ex vivo gene therapy approaches can improve the outcome of islet transplantation for treating type I diabetes. We have recently shown improvement in islet survival and function following ex vivo infection of islets with a mixture of adenoviral vectors encoding human vascular endothelial growth factor (Adv-hVEGF) and human interleukin-1 receptor antagonist (Adv-hIL-1Ra). In this study, we constructed a bicistronic vector encoding these two genes (phVEGF-hIL-1Ra) by cloning hIL-1Ra under the cytomegalovirus (CMV) promoter and hVEGF under the elongation factor-1α (EF-1 α) promoter in pBudCE4.1 vector. There was dose and time dependent expression of hVEGF and hIL-1Ra at both mRNA and protein levels after transfection with human islets. Transfected islets were viable, as evidenced by insulin release upon glucose challenge. Coexpression of hVEGF and hIL-1Ra suppressed nitric oxide production, total caspases, apoptosis, and necrosis in the presence of inflammatory cytokine cocktail consisting of IL-1β, TNFα, and IFNγ. In conclusion, our results indicated that coexpression of growth factor and antiapoptic genes can improve islet survival and function.",
keywords = "Bicistronic plasmid, Human islet, Insulin release, Real-time RT-PCR, hIL-1Ra, hVEGF",
author = "Xiangxu Jia and Kun Cheng and Mahato, {Ram I.}",
year = "2007",
month = "3",
day = "1",
doi = "10.1021/mp060091s",
language = "English (US)",
volume = "4",
pages = "199--207",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society",
number = "2",

}

TY - JOUR

T1 - Coexpression of vascular endothelial growth factor and interleukin-1 receptor antagonist for improved human islet survival and function

AU - Jia, Xiangxu

AU - Cheng, Kun

AU - Mahato, Ram I.

PY - 2007/3/1

Y1 - 2007/3/1

N2 - Ex vivo gene therapy approaches can improve the outcome of islet transplantation for treating type I diabetes. We have recently shown improvement in islet survival and function following ex vivo infection of islets with a mixture of adenoviral vectors encoding human vascular endothelial growth factor (Adv-hVEGF) and human interleukin-1 receptor antagonist (Adv-hIL-1Ra). In this study, we constructed a bicistronic vector encoding these two genes (phVEGF-hIL-1Ra) by cloning hIL-1Ra under the cytomegalovirus (CMV) promoter and hVEGF under the elongation factor-1α (EF-1 α) promoter in pBudCE4.1 vector. There was dose and time dependent expression of hVEGF and hIL-1Ra at both mRNA and protein levels after transfection with human islets. Transfected islets were viable, as evidenced by insulin release upon glucose challenge. Coexpression of hVEGF and hIL-1Ra suppressed nitric oxide production, total caspases, apoptosis, and necrosis in the presence of inflammatory cytokine cocktail consisting of IL-1β, TNFα, and IFNγ. In conclusion, our results indicated that coexpression of growth factor and antiapoptic genes can improve islet survival and function.

AB - Ex vivo gene therapy approaches can improve the outcome of islet transplantation for treating type I diabetes. We have recently shown improvement in islet survival and function following ex vivo infection of islets with a mixture of adenoviral vectors encoding human vascular endothelial growth factor (Adv-hVEGF) and human interleukin-1 receptor antagonist (Adv-hIL-1Ra). In this study, we constructed a bicistronic vector encoding these two genes (phVEGF-hIL-1Ra) by cloning hIL-1Ra under the cytomegalovirus (CMV) promoter and hVEGF under the elongation factor-1α (EF-1 α) promoter in pBudCE4.1 vector. There was dose and time dependent expression of hVEGF and hIL-1Ra at both mRNA and protein levels after transfection with human islets. Transfected islets were viable, as evidenced by insulin release upon glucose challenge. Coexpression of hVEGF and hIL-1Ra suppressed nitric oxide production, total caspases, apoptosis, and necrosis in the presence of inflammatory cytokine cocktail consisting of IL-1β, TNFα, and IFNγ. In conclusion, our results indicated that coexpression of growth factor and antiapoptic genes can improve islet survival and function.

KW - Bicistronic plasmid

KW - Human islet

KW - Insulin release

KW - Real-time RT-PCR

KW - hIL-1Ra

KW - hVEGF

UR - http://www.scopus.com/inward/record.url?scp=34247354627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247354627&partnerID=8YFLogxK

U2 - 10.1021/mp060091s

DO - 10.1021/mp060091s

M3 - Article

C2 - 17256873

AN - SCOPUS:34247354627

VL - 4

SP - 199

EP - 207

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 2

ER -